Australia's CSL boosts profits 19%; Merck trains farmers amid Zilmax scare; U.K. watchdog recommends EGFR tests;

@FiercePharma: With Pfizer, Novartis out, Amgen faces 1 possible rival for Onyx, per Bloomberg: AstraZeneca. Article | Follow @FiercePharma

@EricPFierce: India's Aurobindo buys, boosts capacity in sterile injectables, a hot market. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: Here's the release on Boehringer earnings - BI says Pradaxa, Trajenta, Spiriva driving growth. Release | Follow @CarlyHFierce

> Australia's blood-products specialist CSL posted a 19% increase in profits to $1.2 billion on $5 billion in revenue, buoyed by strong sales of its subcutaneous immunoglobin products. Report

> Merck ($MRK) rolled out a new training program for livestock farmers using its feed additive Zilmax after Tyson Foods barred cattle that fed on the drug, worried about their problems walking or moving. Report

> The National Institute for Health and Care Excellence (NICE) in the U.K. recommended tests for lung cancer patients to determine whether they carry an EGFR gene mutation. Report

> Swiss regulators approved Takeda's new schizophrenia treatment Latuda, known generically as lurasidone. Report

> Drug distributor Celesio cut its outlook for the year, citing a price war with other distributors. Report

Medical Device News

@FierceMedDev: Bard's fate hangs with jury in latest vaginal mesh lawsuit. Article | Follow @FierceMedDev

@DamianFierce: Quintiles is buying Novella with its eye on emerging biotechs. News from FierceCRO.com | Follow @DamianFierce

@MarkHFierce: For LumiQuick, is it another case of regulators trying to assert control over a surging Dx industry? Item | Follow @MarkHFierce

> How did Israel become a hotbed for medical devices? Feature

> FDA sticks 'deadly' tag on Nova's glucose test strips. Report

> Accellent grows revenue but losses widen. Story

> Myriad soars despite rise of rivals. Article

Biotech News

@FierceBiotech: FDA's former IT boss nails down industry gig. Report from FierceBiotechIT.com | Follow @FierceBiotech

@JohnCFierce: MannKind soars after inhaled Afrezza delivers positive PhIII results. Report | Follow @JohnCFierce

@RyanMFierce: Fate Therapeutics, founded by stem cell experts, targets $69 million IPO. Article | Follow @RyanMFierce

> The hottest disease field for biotech startups and M&A might surprise you. More

> Report: Novartis puts a $10B cap on acquisition targets, but steers clear of Onyx. Article

> Industry Voices: The man who cured aging? Article

Drug Delivery News

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Receptor-targeted antifolate drugs yield fewer side effects. More

> Bind files $80M IPO to support PhII nanotech cancer drug delivery. News

> 'Smart' DNA-based nanomeds self-assemble to release cancer drug. Story

> MannKind's inhaled insulin delivery tech passes PhIII trial. Article

> NanoMedical Systems snags $2.3M to develop drug-releasing implant. Item

And F‚Äčinally... A vaccination campaign appears to have stalled a meningitis outbreak in the gay community in New York City. Report